CT:AEZS Aeterna Zentaris Inc.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol AEZS.

This company has cross-listed shares that trade in the U.S. as the symbol AEZS.

5.33 CAD
As of 09/23/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   30,956,234 CAD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy